Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Crosses Into Black for Q3

NEW YORK, Nov. 13 (GenomeWeb News) -Lynx Therapeutics today crossed into the black, reporting net income of $1.8 million for the third quarter of 2003.


"Our operating performance in the third quarter of 2003 reflects higher genomics revenues and continued aggressive management of our expenses," Kevin Corcoran, Lynx's President, said in a statement.


The Hayward, Calif., company's revenues came to $8.3 million for the third quarter, up from $4.8 million for the third quarter of last year.


R&D expenses decreased to $3.0 million, compared to $4.3 million for the same period last year.

As of Sept. 30, Lynx had $6.4 million in cash and cash equivalents, including restricted cash, compared to $11.7 million for the same period last year.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.